Study to Compare Efficacy and Safety of LUBT010 and Lucentis® in Patients With Neovascular AMD

Inclusion Criteria:

1. Ambulatory male or female participants with age ≥ 50 years at the time of screening

2. Capable of understanding and giving written informed consent

3. Primary or recurrent (anti-VEGF naïve) active CNV lesions involving the fovealcenter secondary to AMD

4. BCVA between 20/40 and 20/200 (Snellen equivalent) in the study eye, using ETDRStesting

5. Willingness and ability to undertake all scheduled visits and assessments

Exclusion Criteria:

1. Known hypersensitivity to ranibizumab or any of the components of study medication

2. Known history of allergy to fluorescein dye

3. Scar, fibrosis, or atrophy involving the center of the fovea in the study eye

4. Subretinal hemorrhage in the study eye that involves the center of the fovea

5. Uncontrolled glaucoma

6. Use of prohibited treatments

Other In-/Exclusion criteria may apply